For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the pemphigus vulgaris industry by 2029?
The pemphigus vulgaris market size has grown strongly in recent years. It will grow from $1.80 billion in 2024 to $1.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing adoption of biologic therapies, rising incidence of genetic predisposition, growing prevalence of pemphigus vulgaris, growing role of biosimilars, and growing healthcare infrastructure.
The pemphigus vulgaris market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rise in clinical trials, growth in precision medicine, growth in digital health solutions, increasing demand for biologics, and increasing use of telemedicine. Major trends in the forecast period include advancements in biologic therapies, regulatory approvals, adoption of combination therapies, development in personalized medicine, and innovations in oral formulations of biologic therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22094&type=smp
Which industry-specific innovations are acting as key drivers for the pemphigus vulgaris market?
The prevalence of autoimmune diseases is expected to propel the growth of the pemphigus vulgaris market going forward. Autoimmune diseases are a group of disorders in which the immune system mistakenly attacks and damages the body’s healthy cells, tissues, or organs. The prevalence of autoimmune diseases is increasing due to genetic predisposition, environmental triggers, and lifestyle changes. Genetic factors play a significant role, as individuals with a family history of autoimmune diseases are more likely to develop them due to inherited immune system vulnerabilities. As autoimmune diseases become more common due to genetic predisposition, environmental triggers, and lifestyle changes, more individuals are being diagnosed with conditions like pemphigus vulgaris, driving the demand for advanced therapies. For instance, in January 2025, according to Mayo Clinic Health System, a US-based network of community-based medical facilities that provides comprehensive healthcare services, the global incidence and prevalence of autoimmune diseases are rising, with annual increases estimated at 19.1% and 12.5%, respectively. Therefore, the prevalence of autoimmune diseases is deriving the growth of the pemphigus vulgaris market.
Which segment currently leads the pemphigus vulgaris market in terms of revenue share?
The pemphigus vulgaris market covered in this report is segmented –
1) By Diagnosis And Treatment: Diagnosis, Treatment
2) By Population Type: Pediatric, Adults, Geriatric
3) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Diagnosis: Clinical Examination, Skin Biopsy, Direct Immunofluorescence, Serological Tests, Polymerase Chain Reaction (PCR)
2) By Treatment: Pharmacological Therapy, Non-Pharmacological Therapy
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/pemphigus-vulgaris-global-market-report
What technological trends are expected to redefine the pemphigus vulgaris market?
Major companies operating in the pemphigus vulgaris market are focusing on investment solutions to improve treatment efficacy and expand therapeutic options. Investment solutions involve financial strategies and resources allocated to treatment development, research, and market introduction. For instance, in January 2023, Patient Access Network Foundation (PAN) Foundation, a US-based non-profit organization, launched a financial assistance program to provide up to $6,600 per year for eligible patients with pemphigus vulgaris to cover deductibles, copays, and coinsurance costs. To qualify for financial assistance, patients must undergo treatment for pemphigus vulgaris, have Medicare health insurance covering the necessary medications, and have an income at or below 400% of the federal poverty level. The PAN Foundation also offers transportation assistance and connects patients with support organizations.
Who are the top competitors in the global pemphigus vulgaris market?
Major companies operating in the pemphigus vulgaris market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Amgen Inc., Sanofi S.A, Biogen Inc., Genentech, Genmab A/S, argenx SE, Daewoong Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., Artiva Biotherapeutics, Cabaletta Bio Inc., SinoMab BioScience Limited, Topas Therapeutics GmbH, Principia Biopharma Inc., Serpin Pharma LLC, Syntimmune Inc., International Pemphigus & Pemphigoid Foundation
What regional dynamics are shaping the future of the global pemphigus vulgaris market?
North America was the largest region in the pemphigus vulgaris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pemphigus vulgaris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Pemphigus Vulgaris Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22094
Need Customized Data On Pemphigus Vulgaris Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22094&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
